Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF)

Proteome Science

Volumn 12, Issue 1, 2014, Pages

  Sherma, Nisha D ^a   Borges, Chad R ^a   Trenchevska, Olgica ^a   Jarvis, Jason W ^a   Rehder, Douglas S ^a   Oran, Paul E ^a   Nelson, Randall W ^a   Nedelkov, Dobrin ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Biomarker discovery; Immunoassay; MALDI TOF; MIF; Post translational modifications; Proteomics; Quantification

Indexed keywords

CYTOKINE; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; MASS SPECTROMETRIC IMMUNOASSAY; MASS SPECTROMETRY; MEASUREMENT PRECISION; NORMAL HUMAN; PROTEIN CYSTEINYLATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 84988592746     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/s12953-014-0052-3     Document Type: Article

References (72)

1. Bloom BR, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153(3731):80-82.
2. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1989, 86(19):7522-7526.
3. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R: MIF signal transduction initiated by binding to CD74. J Exp Med 2003, 197(11):1467-1476.
4. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala: CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25(4):595-606.
5. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13(5):587-596.
6. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000, 408(6809):211-216.
7. Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3(10):791-800.
8. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J: Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002, 4(4):449-460.
9. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995, 1(7):781-788.
10. Baugh JA, Donnelly SC: Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 2003, 179(1):15-23.
11. Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, Rorsman H: The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996, 2(1):143-149.
12. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Juttner S, Brunner H, Bernhagen J: Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998, 280(1):85-102.
13. Rosengren E, Aman P, Thelin S, Hansson C, Ahlfors S, Bjork P, Jacobsson L, Rorsman H: The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 1997, 417(1):85-88.
14. Donnelly SC, Bucala R: Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 1997, 3(11):502-507.
15. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377(6544):68-71.
16. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazelzet JA, Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44(10):1321-1328.
17. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, Hoeft A, Stuber F: Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 2001, 27(8):1412-1415.
18. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF: Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999, 42(8):1601-1608.
19. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22(4):309-313.
20. de Mendonca-Filho HT, Gomes RV, de Almeida Campos LA, Tura B, Nunes EM, Gomes R, Bozza F, Bozza PT, Castro-Faria-Neto HC: Circulating levels of macrophage migration inhibitory factor are associated with mild pulmonary dysfunction after cardiopulmonary bypass. Shock 2004, 22(6):533-537.
21. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT: Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med 2004, 117(6):390-397.
22. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C: Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002, 105(13):1561-1566.
23. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, Mizue Y, Bucala R, Simon D: Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24(4):709-714.
24. Garner LB, Willis MS, Carlson DL, DiMaio JM, White MD, White DJ, Adams GA IV, Horton JW, Giroir BP: Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 2003, 285(6):H2500-H2509.
25. Kleemann R, Bucala R: Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010, 2010:610479.
26. Kong YZ, Huang XR, Ouyang X, Tan JJ, Fingerle-Rowson G, Bacher M, Mu W, Scher LA, Leng L, Bucala R, Lan HY: Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 2005, 65(1):272-282.
27. Korshunov VA, Nikonenko TA, Tkachuk VA, Brooks A, Berk BC: Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. Arterioscler Thromb Vasc Biol 2006, 26(2):295-300.
28. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C: Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 2004, 109(3):380-385.
29. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH: Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451(7178):578-582.
30. Yu CM, Lau CP, Lai KW, Huang XR, Chen WH, Lan HY: Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol 2001, 88(7):774-777.
31. Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimburger O, Hu M, Lin X, Stenvinkel P, Miller EJ: Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med 2009, 15(3-4):70-75.
32. Herder C, Kolb H, Koenig W, Haastert B, Muller-Scholze S, Rathmann W, Holle R, Thorand B, Wichmann HE: Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006, 29 (2):368-371.
33. Makino A, Nakamura T, Hirano M, Kitta Y, Sano K, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Kawabata K, Obata JE, Kugiyama K: High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 2010, 213(2):573-578.
34. Yabunaka N, Nishihira J, Mizue Y, Tsuji M, Kumagai M, Ohtsuka Y, Imamura M, Asaka M: Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000, 23(2):256-258.
35. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999, 190(10):1375-1382.
36. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008, 261(2):147-157.
37. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, Mitchell RA: Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007, 282 (41):29910-29918.
38. White ES, Strom SR, Wys NL, Arenberg DA: Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 2001, 166(12):7549-7555.
39. Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G: Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007, 196(4):348. e341-345.
40. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR, Al-Abed Y: Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009, 15(1-2):1-10.
41. Meyer-Siegler K, Iczkowski K, Vera P: Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005, 5(1):73.
42. Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Zhang H, Tian Y, Li Y, Kulasingam V, Drabovich A, Smith CR, Batruch I, Oran PE, Fredolini C, Luchini A, Liotta L, Petricoin E, Diamandis EP, Chan DW, Nelson R, Lopez MF: Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res 2012, 11(8):3986-3995.
43. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24(8):971-983.
44. Gillette MA, Carr SA: Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods 2013, 10(1):28-34.
45. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004, 46(3):313-323.
46. Jensen ON: Modification-specific proteomics: characterization of posttranslational modifications by mass spectrometry. Curr Opin Chem Biol 2004, 8(1):33-41.
47. Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005, 1(5):252-262.
48. Cross JV, Rady JM, Foss FW, Lyons CE, Macdonald TL, Templeton DJ: Nutrient isothiocyanates covalently modify and inhibit the inflammatory cytokine macrophage migration inhibitory factor (MIF). Biochem J 2009, 423(3):315-321.
49. Watarai H, Nozawa R, Tokunaga A, Yuyama N, Tomas M, Hinohara A, Ishizaka K, Ishii Y: Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. Proc Natl Acad Sci U S A 2000, 97(24):13251-13256.
50. Nelson RW, Krone JR, Bieber AL, Williams P: Mass spectrometric immunoassay. Anal Chem 1995, 67(7):1153-1158.
51. Kiernan UA, Nedelkov D, Nelson RW: Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 2006, 5(11):2928-2934.
52. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW: Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 2006, 5(7):1682-1687.
53. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U: Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008, 1(4):258-264.
54. Oran PE, Jarvis JW, Borges CR, Sherma ND, Nelson RW: Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin Appl 2011, 5(7-8):454-459.
55. Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW: Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem 2010, 56(9):1432-1441.
56. Causon R: Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl 1997, 689(1):175-180.
57. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, Khan M, Tacey R, Hill H, Celniker A: Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003, 20(11):1885-1900.
58. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi: Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000, 17(12):1551-1557.
59. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C: Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006, 23(2):312-328.
60. Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8(2):135-160.
61. Bland JM, Altman D: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 327(8476):307-310.
62. Passing H, Bablok: A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983, 21(11):709-720.
63. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE: Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 2009, 8(1):113-117.
64. Hsieh SY, Chen RK, Pan YH, Lee HL: Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006, 6(10):3189-3198.
65. Zhang Q, Tang N, Brock JW, Mottaz HM, Ames JM, Baynes JW, Smith RD, Metz TO: Enrichment and analysis of nonenzymatically glycated peptides: boronate affinity chromatography coupled with electron-transfer dissociation mass spectrometry. J Proteome Res 2007, 6(6):2323-2330.
66. Barnaby OS, Cerny RL, Clarke W, Hage DS: Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2011, 412(3-4):277-285.
67. Gerhardt W, Nordin G, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, Haglund S, Muller-Bardorff M, Katus HA: Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000, 46(6 Pt 1):817-821.
68. Evans MJ, Livesey JH, Ellis MJ, Yandle TG: Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001, 34(2):107-112.
69. Skogstrand K, Ekelund CK, Thorsen P, Vogel I, Jacobsson B, Norgaard-Pedersen B, Hougaard DM: Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. J Immunol Methods 2008, 336(1):78-84.
70. Burd EM: Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 2010, 23(3):550-576.
71. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW: Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003, 44(3):630-639.
72. Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994, 43(5):676-683.